Mercado de la inmunoterapia contra el cáncer en México

Overview of the cancer immunotherapy market in Mexico:

The cancer immunotherapy market in Mexico reached USD 1.7 billion in 2025. Looking ahead, the IMARC Group expects the market to reach USD 3.6 billion by 2034 , exhibiting a compound annual growth rate ( CAGR ) of 8.41% during the period 2026-2034 .  The market is expanding with the increased application of checkpoint inhibitors, the broadening of cancer vaccine uses, and the multifaceted roles of immunomodulators across a range of cancers. These treatments are becoming part of national oncology standards, driven by clinical need and advances in immunotherapies. As adoption expands and applications broaden across different cancer types, the market share of cancer immunotherapy in Mexico continues to grow steadily and strategically.

Trends in the cancer immunotherapy market in Mexico:

Increasing use of checkpoint inhibitors

In Mexico, there is a significant increase in the use of checkpoint inhibitors as they demonstrate their effectiveness in treating other types of cancer, particularly melanoma and non-small cell lung cancer. These drugs target cancer cells by optimizing the immune system's ability to identify and eliminate them, resulting in longer remissions than traditional cancer treatments. Public and private healthcare centers are increasingly adopting checkpoint inhibitor therapies as part of standard treatment protocols, a step toward personalized medicine. Immunological regimens are now the preferred clinical protocols, especially for patients resistant to chemotherapy or radiation therapy. The growth of the cancer immunotherapy market in Mexico remains positive, as patient demand and medical awareness evolve in tandem. According to sources, in March 2023, Mexico began clinical trials of CAR-T cell therapy for blood cancers at the Dr. José Eleuterio González Hospital of the Autonomous University of Nuevo León (UANL), in collaboration with ImmunoACT, the National Polytechnic Institute (IPN), and the Salvador Zubirán National Cancer Institute (ISLN). Furthermore, advances in diagnostic technologies and the availability of biomarker tests have further facilitated the rational use of these therapies, solidifying their inclusion in treatment guidelines. The increasing reliance on immune checkpoint inhibitors is reshaping the therapeutic paradigm and raising the bar for cancer treatment in Mexico.

Expansion of the cancer vaccine

Cancer vaccination is slowly growing in Mexico, driven by increased investment in prevention and therapeutic approaches to immunization. Vaccines are being explored and used not only for cervical and liver cancers, but are also reaching the research phase for lung and colorectal cancers. This need is fueled by a combination of local epidemiological evidence and an urgent need to induce long-lasting immune memory for tumor antigens. Health authority programs and educational campaigns are contributing to increased awareness and early diagnosis, which will be critical for the successful delivery of therapeutic cancer vaccines. Research centers are also actively participating in trials examining the efficacy of vaccines alongside other immunotherapies. As health policy continues to favor advanced cancer care, the development of cancer immunotherapy in Mexico is expected to accelerate. The emphasis on targeted and immune-based therapies is laying the groundwork for cancer vaccines to become an accepted part of standard immuno-oncology practice in the country.

Diversification of the use of immunomodulators in different types of cancer

Immunomodulators, long used to manipulate the immune response, are increasingly being used in various cancers in Mexico, including breast, prostate, and head and neck cancers. For example, in July 2024, Zydus Lifesciences introduced its bevacizumab biosimilar in Mexico, while CAR-T cell trials, CHIPSA treatments, and Immunocine dendritic cell therapies expanded immunotherapy options in 2023 and 2024. Furthermore, these drugs are increasingly being incorporated into multimodal treatment regimens as adjuncts to surgery, radiation therapy, and chemotherapy. Their ability to rebalance immune function makes them particularly useful in cancers that would otherwise not respond to other types of immunotherapies. Thanks to the growing clinical understanding of tumor microenvironments, immunomodulators are being redesigned for more targeted application, optimizing patient outcomes. Physicians are also investigating sequential and combination therapies that include immunomodulators to prevent treatment resistance. The growing clinical acceptance of these therapies has led to their inclusion in national treatment guidelines. Therefore, the use of immunotherapy for cancer in Mexico continues to grow, supported by advances in formulation technologies and immunoprofiling. This trend indicates a developing field in which manipulating immune systems is crucial for achieving prolonged therapeutic effects in oncology.

Segmentation of the cancer immunotherapy market in Mexico:

IMARC Group offers an analysis of key trends in each market segment, along with national and regional forecasts for 2026-2034. Our report has categorized the market based on therapy type, application, and end user.

Perspectives on the type of therapy:

• Monoclonal antibodies
• Cancer vaccines
• Checkpoint inhibitors
• Immunomodulators
• Others

The report offers a detailed breakdown and analysis of the market based on therapy type. This includes monoclonal antibodies, cancer vaccines, checkpoint inhibitors, and immunomodulators, among others.

Application perspectives:

• Lung cancer
• Breast cancer
• Colorectal cancer
• Melanoma
• Prostate cancer
• Head and neck cancer
• Others

The report also provides a detailed breakdown and analysis of the market based on application. This includes lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head and neck cancer, and others.

End-user perspectives:

• Hospitals
• Cancer research centers
• Clinics
• Others

The report offers a detailed breakdown and analysis of the market based on end user. This includes hospitals, cancer research centers, clinics, and others.

Regional perspectives:

• Norte de México
• México Central
• Sur de México
• Otros

El informe también ha proporcionado un análisis exhaustivo de los principales mercados regionales, que incluyen el norte de México, el centro de México, el sur de México y otros.

Panorama competitivo:

El informe de investigación de mercado también ha proporcionado un análisis exhaustivo del panorama competitivo. El informe incluye análisis de la competencia como la estructura del mercado, el posicionamiento de los actores clave, las principales estrategias ganadoras, el cuadro de mando de la competencia y el cuadrante de evaluación de las empresas. También se ofrecen perfiles detallados de las principales empresas.

Noticias sobre el mercado de la inmunoterapia contra el cáncer en México:

• En febrero de 2025, Astellas y Pfizer anunciaron los resultados del ensayo de fase 3 EV-302 a largo plazo de PADCEV® (enfortumab vedotin) más KEYTRUDA® (pembrolizumab), demostrando una mayor eficacia en el tratamiento de primera línea del cáncer urotelial localmente avanzado o metastásico. La combinación mejoró drásticamente la supervivencia libre de progresión y la supervivencia global, consolidando su posición como tratamiento de referencia.

Cobertura del informe sobre el mercado de la inmunoterapia contra el cáncer en México:

Preguntas clave respondidas en este informe:

• ¿Cómo se ha comportado hasta ahora el mercado mexicano de la inmunoterapia contra el cáncer y cómo se comportará en los próximos años?
• ¿Cuál es el desglose del mercado de la inmunoterapia contra el cáncer en México por tipo de terapia?
• ¿Cuál es la distribución del mercado de la inmunoterapia contra el cáncer en México por aplicaciones?
• ¿Cuál es el desglose del mercado mexicano de inmunoterapia contra el cáncer en función del usuario final?
• ¿Cómo se distribuye el mercado de la inmunoterapia contra el cáncer en México por regiones?
• ¿Cuáles son las distintas etapas de la cadena de valor del mercado de la inmunoterapia contra el cáncer en México?
• ¿Cuáles son los principales factores impulsores y los retos de la inmunoterapia contra el cáncer en México?
• ¿Cuál es la estructura del mercado de la inmunoterapia contra el cáncer en México y quiénes son sus principales actores?
• ¿Cuál es el grado de competencia en el mercado de la inmunoterapia contra el cáncer en México?

Principales ventajas para las partes interesadas:

• El informe de la industria de IMARC’s ofrece un análisis cuantitativo integral de varios segmentos del mercado, tendencias históricas y actuales del mercado, pronósticos del mercado y dinámica del mercado de inmunoterapia contra el cáncer en México de 2020 a 2034.
• El informe de investigación proporciona la información más reciente sobre los impulsores del mercado, los retos y las oportunidades en el mercado de la inmunoterapia contra el cáncer en México.
• El análisis de las cinco fuerzas de Porter ayuda a las partes interesadas a evaluar el impacto de los nuevos participantes, la rivalidad competitiva, el poder del proveedor, el poder del comprador y la amenaza de sustitución. Ayuda a las partes interesadas a analizar el nivel de competencia en el sector de la inmunoterapia contra el cáncer en México y su atractivo.
• El panorama competitivo permite a las partes interesadas comprender su entorno competitivo y ofrece una visión de las posiciones actuales de los principales actores del mercado.